COMP <GO>
SDGR vs MRVI // RSI-14 & 200D SMA MOMENTUM
Schrodinger Inc. (NASDAQ) VS. Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: SDGR 6
— MRVI 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MRVI
LAST: $26.19 (-3.50%) • MKT CAP: $2.03B
rsi-technicals
51.8
LAST: $7.19 (-7.94%) • MKT CAP: $2.03B
rsi-technicals
52.2
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SDGR VS. MRVI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SDGR | MRVI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.70% | 18.30% | +37.40 | SDGR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.56% | -3.22% | +3.78 | SDGR | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -40.40% | -60.00% | +19.60 | SDGR | /net-margins <GO> |
| Revenue Growth (YoY) | 23.30% | -28.30% | +51.60 | SDGR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.64 | 3.04 | -0.40 | MRVI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 3/9 | +4.00 | SDGR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 51.8 | 52.2 | -0.40 | MRVI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.03B | $2.03B | $2.2M | SDGR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SDGR REV | MRVI REV | SDGR GROSS % | MRVI GROSS % | SDGR FCF | MRVI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $255.9M | $185.7M | 55.7% | 18.3% | $12.5M | -$70.7M |
| FY 2024 | $207.5M | $259.2M | 63.6% | 41.8% | -$164.7M | -$22.2M |
| FY 2023 | $216.7M | $288.9M | — | — | -$136.7M | $126.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SDGR // BETA —
MRVI // BETA —